These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26758914)

  • 1. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients.
    Dumas G; Habibi A; Onimus T; Merle JC; Razazi K; Mekontso Dessap A; Galactéros F; Michel M; Frémeaux Bacchi V; Noizat Pirenne F; Bartolucci P
    Blood; 2016 Feb; 127(8):1062-4. PubMed ID: 26758914
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
    Sivapalaratnam S; Linpower L; Sirigireddy B; Agapidou A; Jain S; Win N; Tsitsikas DA
    Br J Haematol; 2019 Sep; 186(6):e212-e214. PubMed ID: 31368112
    [No Abstract]   [Full Text] [Related]  

  • 3. Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series.
    Lapite A; Bhar S; Fasipe T
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31061. PubMed ID: 38840429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
    Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-N and anti-Do
    Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
    Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
    Chonat S; Arthur CM; Zerra PE; Maier CL; Jajosky RP; Yee MEM; Miller MJ; Josephson CD; Roback JD; Fasano R; Stowell SR
    Transfus Clin Biol; 2019 May; 26(2):130-134. PubMed ID: 30979566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions.
    Merle NS; Boudhabhay I; Leon J; Fremeaux-Bacchi V; Roumenina LT
    Transfus Clin Biol; 2019 May; 26(2):116-124. PubMed ID: 30879901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
    Pirenne F; Bartolucci P; Habibi A
    Transfus Clin Biol; 2017 Sep; 24(3):227-231. PubMed ID: 28669521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
    Boonyasampant M; Weitz IC; Kay B; Boonchalermvichian C; Liebman HA; Shulman IA
    Transfusion; 2015 Oct; 55(10):2398-403. PubMed ID: 25989361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction.
    Roumenina LT; Bartolucci P; Pirenne F
    Transfus Med Rev; 2019 Oct; 33(4):225-230. PubMed ID: 31672341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion-Transmitted Plasmodium falciparum in a Patient With Sickle Cell Hemoglobinopathy.
    Valliani S; Agasthi P; Westney G; Foreman M
    Ann Intern Med; 2018 Sep; 169(6):417-418. PubMed ID: 29801034
    [No Abstract]   [Full Text] [Related]  

  • 13. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
    Lee LE; Beeler BW; Graham BC; Cap AP; Win N; Chen F
    Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with plasma exchange in life-threatening hyperhemolytic syndrome unrelated to sickle cell disease.
    Shaulov A; Rund D; Filon D; Nachmias B; Khalili A; Manny N; Zelig O
    Transfusion; 2023 May; 63(5):1100-1106. PubMed ID: 36866433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease.
    Chonat S; Quarmyne MO; Bennett CM; Dean CL; Joiner CH; Fasano RM; Stowell SR
    Haematologica; 2018 Oct; 103(10):e483-e485. PubMed ID: 29794144
    [No Abstract]   [Full Text] [Related]  

  • 16. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.
    Vidler JB; Gardner K; Amenyah K; Mijovic A; Thein SL
    Br J Haematol; 2015 Jun; 169(5):746-53. PubMed ID: 25753472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion.
    Weinstock C; Möhle R; Dorn C; Weisel K; Höchsmann B; Schrezenmeier H; Kanz L
    Transfusion; 2015 Mar; 55(3):605-10. PubMed ID: 25251967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperhaemolytic transfusion reaction in two β-thalassaemia major patients: The role of eculizumab.
    Pantelidou D; Pilalas D; Daios S; Polychronopoulos G; Papadopoulou D; Perifanis V; Savopoulos C; Kaiafa G
    J Clin Pharm Ther; 2022 Mar; 47(3):411-414. PubMed ID: 34397109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed haemolytic transfusion reactions in patients with sickle cell disease.
    Cummins D; Webb G; Shah N; Davies SC
    Postgrad Med J; 1991 Jul; 67(789):689-91. PubMed ID: 1924062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected Anemia and Reticulocytopenia in an Adolescent With Sickle Cell Anemia Receiving Chronic Transfusion Therapy.
    Blauel ER; Grossmann LT; Vissa M; Miller ST
    J Pediatr Hematol Oncol; 2015 Oct; 37(7):e438-40. PubMed ID: 26207780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.